Teva Wins Ruling on Patents for Bendeka Cancer Drug
- Patents’ validity upheld by federal judge in Delaware
- Bendeka has faster infusion time than Teva’s Treanda treatment
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. won a ruling that could keep its cancer drug Bendeka free from generic competition for more than a decade.
A federal judge in Delaware on Monday ruled that proposed generic versions of Bendeka by Mylan NV, Fresenius SE’s Fresenius Kabi, closely held Apotex Inc. and Slayback Pharma LLC infringe as many as four Teva patents on the drug, which has generated more than $2 billion in sales since its 2016 launch.